DE69132681D1 - Klonierung und Expression von Borrelia Lipoproteinen - Google Patents
Klonierung und Expression von Borrelia LipoproteinenInfo
- Publication number
- DE69132681D1 DE69132681D1 DE69132681T DE69132681T DE69132681D1 DE 69132681 D1 DE69132681 D1 DE 69132681D1 DE 69132681 T DE69132681 T DE 69132681T DE 69132681 T DE69132681 T DE 69132681T DE 69132681 D1 DE69132681 D1 DE 69132681D1
- Authority
- DE
- Germany
- Prior art keywords
- ospa
- pet9
- borrelia
- cloning
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000589968 Borrelia Species 0.000 title abstract 2
- 102000004895 Lipoproteins Human genes 0.000 title abstract 2
- 108090001030 Lipoproteins Proteins 0.000 title abstract 2
- 208000016604 Lyme disease Diseases 0.000 title abstract 2
- 238000010367 cloning Methods 0.000 title abstract 2
- 101710105714 Outer surface protein A Proteins 0.000 abstract 3
- 101900341263 Borrelia burgdorferi Outer surface protein A Proteins 0.000 abstract 2
- 230000003321 amplification Effects 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 108090000233 Signal peptidase II Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 238000003752 polymerase chain reaction Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Saccharide Compounds (AREA)
- External Artificial Organs (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63207290A | 1990-12-21 | 1990-12-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69132681D1 true DE69132681D1 (de) | 2001-09-13 |
| DE69132681T2 DE69132681T2 (de) | 2001-11-22 |
Family
ID=24533958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69132681T Expired - Lifetime DE69132681T2 (de) | 1990-12-21 | 1991-12-18 | Klonierung und Expression von Borrelia Lipoproteinen |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5571718A (de) |
| EP (1) | EP0492964B1 (de) |
| JP (1) | JP2706397B2 (de) |
| AT (1) | ATE204020T1 (de) |
| AU (1) | AU656159B2 (de) |
| CA (1) | CA2057536C (de) |
| DE (1) | DE69132681T2 (de) |
| DK (1) | DK0492964T3 (de) |
| FI (1) | FI105924B (de) |
| IE (1) | IE66473B1 (de) |
| IL (1) | IL100422A0 (de) |
| NO (1) | NO303453B1 (de) |
| PT (1) | PT99918B (de) |
| ZA (1) | ZA919965B (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4015911A1 (de) * | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | Impfstoff gegen die lyme-krankheit |
| CA2084413A1 (en) | 1990-06-15 | 1991-12-16 | Richard A. Flavell | Compositions and methods for the prevention and diagnosis of lyme disease |
| US6676942B1 (en) * | 1991-08-15 | 2004-01-13 | Smithkline Beecham Biologicals (S.A.) | Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
| DE69229476T2 (de) * | 1991-08-15 | 2000-03-16 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe |
| WO1993008299A1 (en) * | 1991-10-18 | 1993-04-29 | Connaught Laboratories Inc. | Preparation of recombinant borrelia proteins |
| BE1006728A3 (fr) * | 1993-02-19 | 1994-11-29 | Wallone Region | Sondes d'acides nucleiques specifiques au spirochete borrelia burgdorferi. |
| US5439808A (en) * | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
| US6004534A (en) * | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
| US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
| US5747287A (en) * | 1995-04-28 | 1998-05-05 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
| AU2191597A (en) * | 1996-02-21 | 1997-09-10 | Board Of Regents, The University Of Texas System | Vmp-like sequences of pathogenic borrelia |
| US5846946A (en) * | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
| AU722630B2 (en) * | 1997-02-14 | 2000-08-10 | Higeta Shoyu Co., Ltd. | Modified Treponema pallidum-derived antigen protein |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6689573B1 (en) * | 1999-05-24 | 2004-02-10 | New England Biolabs, Inc. | Method for screening restriction endonucleases |
| DE60131982T2 (de) | 2000-08-18 | 2008-12-11 | Brookhaven Science Associates Llc | Veränderte borrelia burgdorferi ospa |
| US7729322B2 (en) * | 2002-02-28 | 2010-06-01 | Qualcomm Incorporated | HDLC hardware accelerator |
| WO2004058181A2 (en) | 2002-12-20 | 2004-07-15 | Board Of Regents, The University Of Texas System | Vmp-like sequences of pathogenic borrelia species and strains |
| EP2283031B1 (de) * | 2008-05-02 | 2017-04-12 | Virginia Commonwealth University | Impfstoff gegen die lyme-krankheit |
| CA3095174A1 (en) * | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic ospa polypeptides |
| US20220229055A1 (en) * | 2021-01-15 | 2022-07-21 | Id-Fish Technology, Inc. | Species-specific antigen sequences for tick-borne relapsing fever (tbrf) and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK590288D0 (da) * | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
| DE4015911A1 (de) * | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | Impfstoff gegen die lyme-krankheit |
| CA2084413A1 (en) * | 1990-06-15 | 1991-12-16 | Richard A. Flavell | Compositions and methods for the prevention and diagnosis of lyme disease |
| EP1016416A3 (de) * | 1990-07-06 | 2002-10-23 | Wyeth | Impfstoff gegen die Lyme-Krankheit und Modell zur Überwachung der Impfstoffwirksamkeit |
-
1991
- 1991-12-12 CA CA002057536A patent/CA2057536C/en not_active Expired - Fee Related
- 1991-12-18 ZA ZA919965A patent/ZA919965B/xx unknown
- 1991-12-18 DE DE69132681T patent/DE69132681T2/de not_active Expired - Lifetime
- 1991-12-18 AT AT91311758T patent/ATE204020T1/de not_active IP Right Cessation
- 1991-12-18 AU AU89834/91A patent/AU656159B2/en not_active Ceased
- 1991-12-18 DK DK91311758T patent/DK0492964T3/da active
- 1991-12-18 EP EP91311758A patent/EP0492964B1/de not_active Expired - Lifetime
- 1991-12-19 FI FI916023A patent/FI105924B/fi not_active IP Right Cessation
- 1991-12-19 IL IL100422A patent/IL100422A0/xx unknown
- 1991-12-19 IE IE444991A patent/IE66473B1/en not_active IP Right Cessation
- 1991-12-20 NO NO915051A patent/NO303453B1/no unknown
- 1991-12-20 PT PT99918A patent/PT99918B/pt not_active IP Right Cessation
- 1991-12-21 JP JP3361129A patent/JP2706397B2/ja not_active Expired - Fee Related
-
1992
- 1992-09-08 US US07/941,523 patent/US5571718A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US5571718A (en) | 1996-11-05 |
| EP0492964A2 (de) | 1992-07-01 |
| JP2706397B2 (ja) | 1998-01-28 |
| CA2057536A1 (en) | 1992-06-22 |
| AU656159B2 (en) | 1995-01-27 |
| NO915051L (no) | 1992-06-22 |
| FI105924B (fi) | 2000-10-31 |
| NO303453B1 (no) | 1998-07-13 |
| IE914449A1 (en) | 1992-07-01 |
| CA2057536C (en) | 1999-10-26 |
| AU8983491A (en) | 1992-06-25 |
| PT99918B (pt) | 1999-08-31 |
| FI916023A0 (fi) | 1991-12-19 |
| ATE204020T1 (de) | 2001-08-15 |
| ZA919965B (en) | 1992-11-25 |
| PT99918A (pt) | 1992-12-31 |
| FI916023A (fi) | 1992-06-22 |
| IE66473B1 (en) | 1995-12-27 |
| JPH0641195A (ja) | 1994-02-15 |
| EP0492964A3 (en) | 1993-02-24 |
| EP0492964B1 (de) | 2001-08-08 |
| NO915051D0 (no) | 1991-12-20 |
| DK0492964T3 (da) | 2001-10-08 |
| DE69132681T2 (de) | 2001-11-22 |
| IL100422A0 (en) | 1992-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE204020T1 (de) | Klonierung und expression von borrelia lipoproteinen | |
| NO832848L (no) | Gjaerhybridvektorer og deres bruk ved fremstillingen av polypeptider | |
| ATE71660T1 (de) | Autonome replikationssequenzen fuer hefestaemme des genus pichia. | |
| ATE283916T1 (de) | Menschliche metabotropische glutamatrezeptor untertype hmglur7 und verwandte dns-verbindungen | |
| FR2637612B1 (fr) | Sequences de nucleotides codant pour une proteine a activite ureasique | |
| FI875427A0 (fi) | Menetelmä valmistaa hevosen -interferonia | |
| CA2066370A1 (en) | Yield when disulfide-bonded proteins are secreted | |
| FI971100A (fi) | Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi | |
| FI824238L (fi) | Foerfarande och vektororganism foer ackumulering av klonade heterologa genprodukter reglerat i bacillus subtilis ii | |
| ES2170082T3 (es) | Transactivador de mhc clase ii (ciita) y sus usos. | |
| DK595187D0 (da) | Minactivin og fremgangsmaade til fremstilling deraf | |
| DE60124380D1 (de) | Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure | |
| DK210288A (da) | Overproduktion af exocelllulaere proteiner | |
| AU6999287A (en) | Insecticidal proteinaceous substance | |
| KR970702920A (ko) | 시스-3-히드록시-엘-프롤린의 제조법(process for producing cis-3- hydroxy-l-proline) | |
| DK1241186T4 (da) | Humant vækststandsende specifikt gen-6 (gas-6) og nukleinsyrer kodende derfor | |
| ES8506800A1 (es) | Un metodo de fabricar un vector de plasmido recombinante deseado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |